Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Hunter Capital AB (Publ) currently maintains 1 pending office action in the Biotechnology & Pharmaceuticals technology area. All active prosecution is situated within 1 distinct art unit, showing a very focused technical and administrative scope. This lack of distribution across art units suggests a specialized set of filings that are being evaluated under a set of departmental standards. This concentration can lead to a more predictable prosecution path for the applicant as they navigate the complexities of biotechnology patent law.
The portfolio is managed by 1 distinct examiner, FAY, ZOHREH ALEMZADEH, who is currently handling 1 pending office action. Because this examiner is the individual reviewing the company's pending work, their specific examination habits will dictate the immediate trajectory of the portfolio. The prosecution strategy is currently simplified by this examiner relationship, allowing for a more personal and direct approach to resolving any outstanding issues in the pending application without the need for diverse strategies across multiple examiners. Success depends on meeting the specific evidentiary standards required by this official.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FAY, ZOHREH ALEMZADEH | 1 | 52.2% | -6.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17907953 | NEW USE AND METHOD OF TREATMENT | FAY, ZOHREH ALEMZADEH | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17907953 | NEW USE AND METHOD OF TREATMENT | FAY, ZOHREH ALEMZADEH | 1617 | §103§112 | Non-Final OA | — | Pending | Aug 29, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial